ResMed Faces Turbulence: Is Sleep Apnea Treatment Still a Smart Investment?
ResMed’s stock fell over 6% due to concerns over slower sales growth. The company reported strong earnings of $1.28 billion, up 10% year-on-year. U.S. sales of CPAP masks increased significantly, though international sales lagged. Adjusted earnings reached $2.43 per share, exceeding analyst